نتایج جستجو برای: hybridoma

تعداد نتایج: 2172  

Journal: :The Journal of Experimental Medicine 1983
I Takei T Sumida M Taniguchi

An acceptor hybridoma with a receptor that recognizes the keyhole limpet hemocyanin (KLH)-specific suppressor T cell factor (KLH-TsF) was established after the fusion of C57BL/6 splenic T cells enriched with KLH-coated petri dishes. The cloned hybridoma (34S-281) could be specifically activated by stimulation with the conventional KLH-TsF or monoclonal KLH-TsF from three different hybridomas in...

Journal: :The Journal of Experimental Medicine 1997
Jeffrey L. Seibel Nancy Wilson Haruo Kozono Philippa Marrack John W. Kappler

The alpha/beta T cell receptor (TCR) recognizes peptide fragments bound in the groove of major histocompatibility complex (MHC) molecules. We modified the TCR alpha chain from a mouse T cell hybridoma and tested its ability to reconstitute TCR expression and function in an alpha chain-deficient variant of the hybridoma. The modified alpha chain differed from wild type only in its leader peptide...

2015
Haolin Liu Janice White Frances Crawford Niyun Jin Xiangwu Ju Kangtai Liu Chengyu Jiang Philippa Marrack Gongyi Zhang John W. Kappler John S Tregoning

B cell hybridomas are an important source of monoclonal antibodies. In this paper, we developed a high-throughput method to characterize mouse IgG antibodies using surface plasmon resonance technology. This assay rapidly determines their sub-isotypes, whether they bind native antigen and their approximate affinities for the antigen using only 50 μl of hybridoma cell culture supernatant. Moreove...

Journal: :BMC Biotechnology 2008
Natalie Gavrilov-Yusim Ekaterina Hahiashvili Marina Tashker Victoria Yavelsky Ohad Karnieli Leslie Lobel

BACKGROUND The isolation and production of human monoclonal antibodies is becoming an increasingly important pursuit as biopharmaceutical companies migrate their drug pipelines away from small organic molecules. As such, optimization of monoclonal antibody technologies is important, as this is becoming the new rate-limiting step for discovery and development of new pharmaceuticals. The major li...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2006
Jian Li Tao Sai Marc Berger Qimin Chao Diane Davidson Gaurav Deshmukh Brian Drozdowski Wolfgang Ebel Stephen Harley Marianne Henry Sara Jacob Brad Kline Ella Lazo Frank Rotella Eric Routhier Kathryn Rudolph Jeaneen Sage Paul Simon Jun Yao Yuhong Zhou Mani Kavuru Tracey Bonfield Mary Jane Thomassen Philip M Sass Nicholas C Nicolaides Luigi Grasso

Current strategies for the production of therapeutic mAbs include the use of mammalian cell systems to recombinantly produce Abs derived from mice bearing human Ig transgenes, humanization of rodent Abs, or phage libraries. Generation of hybridomas secreting human mAbs has been previously reported; however, this approach has not been fully exploited for immunotherapy development. We previously ...

Journal: :The Journal of biological chemistry 1982
L K Curtiss T S Edgington

Apolipoprotein B obtained from each of the major density classes of human plasma lipoproteins was investigated immunochemically. Eleven different mouse hybridoma cell lines were generated and selected on the basis of their ability to secrete antibodies that were bound by either very low density or intermediate density lipoproteins. Two of these antibodies appeared to be specific for complex epi...

Journal: :Memórias do Instituto Oswaldo Cruz 1988

Journal: :The Journal of clinical investigation 1986
J Rauch H Tannenbaum K Straaton H Massicotte J Wild

Human hybridomas have been produced by fusing peripheral blood lymphocytes from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) with the GM 4672 human cell line. 262 hybridoma clones from the fusions of four RA and five SLE patients were screened for binding to denatured DNA (dDNA), native DNA, and the Fc fragment of human IgG (HIgG). Of the 17 hybridoma antibodie...

2010
Maurizio Bendandi

Hybridoma-derived idiotype vaccines have been used for the experimental treatment of human lymphoma over the last twenty years, providing evidence of biological efficacy, clinical efficacy and clinical benefit. However, the product that has come closer to regulatory approval is unlikely to clear that hurdle due to the insufficiently robust data obtained in a recently closed clinical trial. This...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید